Last reviewed · How we verify
Reparixin continuous infusion
Reparixin continuous infusion is a Small molecule drug developed by Dompé Farmaceutici S.p.A. It is currently in Phase 2 development. Also known as: REP.
Reparixin is a small molecule modulator of the interleukin-8 receptor A, classified as a MODULATOR. It has been studied in clinical trials for various conditions, including ischemia-reperfusion injury, kidney diseases, and early allograft dysfunction, using continuous infusion as an intervention.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Reparixin continuous infusion |
|---|---|
| Also known as | REP |
| Sponsor | Dompé Farmaceutici S.p.A |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation (PHASE2)
- Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation (PHASE2)
- Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation (PHASE2)
- Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation (PHASE3)
- Reparixin in Pancreatic Islet Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reparixin continuous infusion CI brief — competitive landscape report
- Reparixin continuous infusion updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI
Frequently asked questions about Reparixin continuous infusion
What is Reparixin continuous infusion?
Who makes Reparixin continuous infusion?
Is Reparixin continuous infusion also known as anything else?
What development phase is Reparixin continuous infusion in?
Related
- Manufacturer: Dompé Farmaceutici S.p.A — full pipeline
- Also known as: REP
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing